Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

254.66

+9.78 (3.99%)

as of Jun 26, 2026, 8:00:00 pm Market Open.

696 watching

Investor Insights

Jun 28, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has garnered a generally positive outlook from various experts, particularly highlighting its strong performance in pharmaceuticals and medical devices after a recent spin-off of its orthopedics division. The company's robust drug pipeline is considered one of the best in the industry, contributing to a resilient stock performance even amidst market volatility. While there is a legal overhang due to ongoing talcum powder lawsuits, experts suggest that this has diminished in significance. The company's valuation appears reasonable, and many experts encourage buying on weakness, reflecting confidence in future growth prospects. Overall, JNJ is seen as a solid investment, especially for those interested in dividend growth and long-term potential.

Consensus

Positive

Valuation

Fair Value

Similar

HOLD

Attractive stock for a long-term investor. Has been consistently beating estimates and estimates have been rising. As volatility comes out of the market, people are going to be willing to pay for this level of quality.

Wealthica Track your Stocks in your Watch List

TOP PICK

Have medical devices, consumer products and pharmaceuticals. Acquisition of Pfizer's consumer products division in 2006 was very good. Fantastic balance sheet. Net cash.

TOP PICK

Good company to own in this kind of a difficult market. Not only a pharmaceutical and medical devices company but also a consumers product company. Made an astute acquisition of Pfizer's (PFE-N) consumers’ products. Almost 6% dividend.

TRADE

Have medical Device business, Consumer business, great company, a lot of which is not sensitive to politics.

BUY

Very interesting, very stable.

BUY

Diversified medical supply and pharmaceutical. Hitting new highs but valuation is still among the cheapest at 15X earnings. Double-digit growth through many years. 2.6% yield. Has a little bit of upside left. Long-term hold.

BUY

Consumer products and pharmaceuticals. Has the confidence of the shareholders and has done very well. Strong balance sheet. Stable company. Well-placed for a growth environment.

BUY

Great company and has been an excellent stock. Really isn't a pharmaceutical stock. Big in medical devices. Also a large consumers product company.

TOP PICK

Recently had a huge breakout. Had not cleared the $70 for ages. People who had shorted are now scrambling to cover. You don't want to be in this event starts coming back too far.

BUY

Home healthcare products and health/beauty aids are very solid products in the US. Less enthusiastic about the medical devices business and pharmaceuticals but overall it is a tremendously strong company with a very good dividend. Has been undervalued for about 5 years.

TOP PICK

(Sneaked in a 4th Top Pick.) An absolutely unbelievable technical breakout. Had not gone past its $69-$70 level since 2005. See it heading towards the $100 level.

BUY

Medical Device manufacturing. Should be a core holding for conservative investors. They have good growth projects. 40%-50% international exposure

BUY

Stable cash flow. A solid name to own in these volatile markets.

DON'T BUY

Over time, the model price has been coming down. He has a model price of $60.18, a -14% differential.

TOP PICK

Medical devices and pharmaceuticals have been doing very well. Has a global franchise and growing very nicely outside of North America. Positive earnings revisions.

Showing 496 to 510 of 626 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Kevin Simpson

Capital Wealth Planning

Bryn Talkington

Requisite Capital Management

Andrey Omelchak

LionGuard Capital Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)